Nrf2激活剂用于治疗罕见的铁过载疾病:从长椅到床边
Yimin Dong1, Meng Zheng1, Weizhong Ding2
1Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Redox biology
|February 18, 2025
概括
Nrf2激活剂通过降低铁含量和氧化应激来治疗罕见的铁过载疾病具有前景. 与铁化剂的联合治疗可能会提高这些疾病的治疗疗效.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 罕见疾病通常涉及铁过载和氧化损伤,这是由于影响铁平衡的遗传突变造成的.
- 核因素红色素2相关因子2 (Nrf2) 调节细胞抗氧化反应,并可以通过影响与铁相关的基因和途径来降低铁含量.
研究的目的:
- 探索Nrf2激活剂对罕见铁过载疾病的治疗潜力,机制和预防措施.
- 建议使用Nrf2激活剂和铁合剂进行组合治疗,以加强临床应用.
主要方法:
- 关于Nrf2激活剂和铁过载障碍的文献综述.
- 对参与铁调节和氧化应激的Nrf2-介导通路的分析.
- 评估现有临床实例和拟议的组合策略.
主要成果:
- Nrf2激活剂在管理某些罕见疾病中的铁过载和氧化损伤方面是有效的.
- 奥马维洛克索隆和二甲基烟酸是Nrf2激活剂治疗的成功例子.
- Nrf2激活剂在治疗更广泛的铁过载障碍方面的潜力是显著的,但可能被忽视.
结论:
- Nrf2激活剂是罕见的铁过载疾病的有前途的治疗策略.
- 需要进一步研究和临床应用Nrf2激活剂,可能与铁合剂结合使用.
- 这种方法可以显著有利于患有各种铁过载条件的患者.
相关概念视频
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Erythropoiesis
4.0K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.0K
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K


